| |
|
|
|
Xtalks, Online
2025-12-04
During monoclonal antibody manufacturing, process-related impurities such as host cell proteins and protein A can affect product safety, activity, quality and stability. Downstream purification processes aim to remove these impurities, and residual levels must be minimized in the final product. Using a case study, this webinar will introduce a novel automated immunoassay-based alternative using nanoliter-scale microfluidics in place of ELISA, which is considered the gold standard method for impurity quantification.
In this case study, the platform was used to quantify residual host cell proteins, measure and titrate the antibody and verify that the antibody binds specifically to its target (target binding assay) in bioprocess samples. The study demonstrates how the new technology can streamline clinical batch release testing as a reliable alternative to conventional ELISA.
Register for this webinar to learn how automated immunoassay solutions can streamline impurity quantification and clinical batch release.
Keywords: Assay, Bioanalytical Testing, CDMO/CMO, CMC, Downstream Processing, Drug Development, ELISA, Immunoassays, Laboratory Technology, Monoclonal Antibody, Other Software, Process Development, Protein Purification, Quality, Quality Control
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Fabrice Cantais, Senior Scientist, Analytical Leader for Biologics, Servier
Kira Hedström, Application Scientist, Gyros Protein Technologies
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-12-04
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|